Expert panel assesses project proposals
With GO-Bio next, the BMFTR supports teams of scientists from the life sciences who are ready to found a company.
A jury of experts from science and industry will select the best ideas with the most promising teams from all the project proposals submitted.
The project proposals for GO-Bio next funding go through a two-stage process.
A panel of experts with representatives from the international biotechnology and finance scene assesses the project applications for both phases of GO-Bio next. After a pre-selection, prioritised teams can present their projects to the jury. As a result of this jury meeting, the BMFTR receives proposals for funding projects in GO-Bio next. The final funding decision is reserved for the BMFTR as the funding body.
Evaluation criteria for the selection of project ideas:
- Innovation level of the project
- Economic exploitation potential and spin-off prospects
- Qualification, suitability and composition of the project team
- Quality of the R&D concept and the description of the work, time and milestone plan
- Plausibility of the financing plan
Members of the expert panel:
- Silke Beaucamp, BEAUCAMP Unternehmensberatung
- Stefan B. Beerhalter, BIZZ GmbH
- Annegret de Baey-Diepolder, Seventure Partners
- Juergen Gamer, TET Systems GmbH und Co. KG
- Thomas Hanke, Venture Partner, CARMA Fund
- Peter Heinrich, Sinfonie Life Science Management GmbH
- Thomas Höger, Apogenix GmbH
- Svenja Jarchow-Pongratz, Center for Entrepreneurial and Financial Studies, Technische Universität München
- Sebastian Kreuz, Boehringer Ingelheim Venture Fund GmbH
- Ulrich Mahr, Max-Planck-Innovation GmbH
- Ute Mercker, IBB Ventures
- Marianne Mertens, Apollo Health Ventures
- Harald Poth, Independent Life Science Investment Consultant
- Christoph Rußmann, Health Campus Göttingen, University of Applied Sciences and Arts, Faculty of Engineering and Health
- Rupert Sandbrink, SDDCCS: Sandbrink Drug Development - Consulting and Clinical Services
- Isabel N. Schellinger, Angiolutions GmbH
- Andreas Schmidt, Springboard Health Ventures GmbH
- Heinz Schwer, Independent Consultant
- Martha Smets, Family Office
- Michael Thiel, Sanemus AG
- Fei Tian, MIG Capital AG
- Karen Uhlmann, OMEICOS Therapeutics GmbH
- Angelika Vlachou, High-Tech Gründerfonds (HGTF)
- Jens Wiehler, Co-Founder, Biotech Company in formation (@Max-Planck Gesellschaft)
- Johannes B. Wöhrstein, mbiomics GmbH